BACKGROUND atopic dermatitis and asthma are two diseases whose pathogenesis is largely attributable to the activation, at least in the initial stages, of T helper (Th)-2 Lymphocytes, the related cytokine axis, and B lymphocytes with antibody production. psoriasis is conversely a pathology resulting from a recruitment of Th-17 and Th-1 lymphocytes, after an initial role of innate immunity. mepolizumab is a humanized monoclonal antibody directed against interleukin (IL)-5, a central cytokine in the Th-2 axis, therefore involved in the pathogenesis of asthma. several authors have described the appearance of psoriatic lesions in patients with asthma or atopic dermatitis following the therapy with dupilumab, a monoclonal antibody that blocks the interleukin (IL)-4, another Th-2 cytokine.CASE SUMMARYWe present the case of a 59-year-old patient who developed psoriasiform lesions on the palms after mepolizumab therapy for asthma, for the activation of the parallel cytokine cascade after the blockade of IL-5. we successfully treated the patient with a topical calcipotriol and betamethasone ointment.CONCLUSIONWe should investigate with further attention the possible impact on the human immunological ecosystem put in place by the inhibition of the activity of individual inflammatory mediators, so as to be able to recognize the initial adverse effects early.

Artosi, F., Diluvio, L., Vultaggio, M., Campione, E., Bianchi, L. (2023). Mepolizumab induced palmoplantar psoriasis: A case report. WORLD JOURNAL OF CLINICAL CASES, 11(26), 6154-6158 [10.12998/wjcc.v11.i26.6154].

Mepolizumab induced palmoplantar psoriasis: A case report

Artosi, Fabio;Vultaggio, Martina;Campione, Elena;Bianchi, Luca
2023-09-16

Abstract

BACKGROUND atopic dermatitis and asthma are two diseases whose pathogenesis is largely attributable to the activation, at least in the initial stages, of T helper (Th)-2 Lymphocytes, the related cytokine axis, and B lymphocytes with antibody production. psoriasis is conversely a pathology resulting from a recruitment of Th-17 and Th-1 lymphocytes, after an initial role of innate immunity. mepolizumab is a humanized monoclonal antibody directed against interleukin (IL)-5, a central cytokine in the Th-2 axis, therefore involved in the pathogenesis of asthma. several authors have described the appearance of psoriatic lesions in patients with asthma or atopic dermatitis following the therapy with dupilumab, a monoclonal antibody that blocks the interleukin (IL)-4, another Th-2 cytokine.CASE SUMMARYWe present the case of a 59-year-old patient who developed psoriasiform lesions on the palms after mepolizumab therapy for asthma, for the activation of the parallel cytokine cascade after the blockade of IL-5. we successfully treated the patient with a topical calcipotriol and betamethasone ointment.CONCLUSIONWe should investigate with further attention the possible impact on the human immunological ecosystem put in place by the inhibition of the activity of individual inflammatory mediators, so as to be able to recognize the initial adverse effects early.
16-set-2023
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35
English
Asthma
Case report
Immunology
Interleukin-5
Mepolizumab
Psoriasis
Artosi, F., Diluvio, L., Vultaggio, M., Campione, E., Bianchi, L. (2023). Mepolizumab induced palmoplantar psoriasis: A case report. WORLD JOURNAL OF CLINICAL CASES, 11(26), 6154-6158 [10.12998/wjcc.v11.i26.6154].
Artosi, F; Diluvio, L; Vultaggio, M; Campione, E; Bianchi, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
WJCC-11-6154 Mepolizumab induced palmoplantar psoriasis.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.7 MB
Formato Adobe PDF
2.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/359725
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact